Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients
Phase of Trial: Phase I/II
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Maraviroc (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics; Therapeutic Use
- 19 Mar 2019 Status changed from recruiting to completed.
- 18 Sep 2018 Planned number of patients changed from 65 to 30.
- 25 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.